Company Overview of Precision BioSciences, Inc.
Precision BioSciences, Inc., a biotechnology company, engages in developing and commercializing therapeutics and services based on genomic molecular biology. It offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock. The company was founded in 2006 and is based in Research Triangle Park, North Carolina.
302 East Pettigrew Street
Dibrell Building Suite A-100
Durham, NC 27701
Founded in 2006
Key Executives for Precision BioSciences, Inc.
Co-Founder, Chief Executive Officer and Director
Chief Operations Officer and Chief Financial Officer
Senior Vice President of Gene Therapy
Senior Vice President of Cell Therapy
Compensation as of Fiscal Year 2016.
Precision BioSciences, Inc. Key Developments
Baxalta Enters into a Global Collaboration with Precision Biosciences
Mar 1 16
Baxalta has announced that it has entered into a global collaboration with Precision Biosciences (US) to develop a broad series of allogeneic chimeric antigen receptor (CAR) T-cell therapies directed towards multiple cancers. Under the terms of the deal, the two companies will develop CAR T therapies for up to six unique targets, with the first programme expected to enter clinical studies in late 2017. Precision will conduct early-stage research activities up to Phase II, after which Baxalta has exclusive rights to late-stage development and commercialisation. Precision will receive an upfront payment of USD 105 million from Baxalta, with additional option fees and milestones potentially totaling up to USD 1.6 billion, in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialisation of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. The collaboration will make use of Precision BioSciences' proprietary ARCUS genome editing technology, which enables the production of CAR T cells derived from healthy donors rather than relying on the patient. This approach aims to overcome the manufacturing limitations of existing CAR T therapies and enable the targeting of a broader range of malignancies.
Baxalta Incorporated and Precision Biosciences Announces Global Collaboration to Develop Broad Series of Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapies
Feb 25 16
Baxalta Incorporated and Precision BioSciences announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. CAR T is widely recognized as a breakthrough technology with the potential to become a curative option for certain malignancies. Most CAR T cell therapy technologies isolate cells from cancer patients’ blood and re-engineer them to specifically target receptors on tumor cells. The reprogrammed cells are multiplied in a laboratory and then returned to the patient to target the tumor. This approach has had initial success in clinical trials for certain tumor types, but persistent scaling challenges remain based on the highly personalized nature of the therapy. Precision BioSciences’ proprietary ARCUS genome editing technology enables the production of CAR T cells derived from healthy donors rather than relying on the patient. This approach aims to overcome the manufacturing-related limitations with existing CAR T therapies and enable a broader range of malignancies to be targeted. Under the terms of the agreement, Baxalta and Precision BioSciences will develop CAR T therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017. Precision BioSciences will be responsible for performing early-stage research activities up to Phase 2, following which Baxalta has the exclusive right to opt in for late-stage development and commercialization. Precision BioSciences will receive an upfront payment of $105 million from Baxalta, with additional option fees, developmental, clinical, regulatory, and sales milestones, potentially totaling up to $1.6 billion, in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. Additional terms and initial targets were not disclosed. The agreement follows another recently established Baxalta collaboration to advance novel therapeutics against checkpoint targets, advancing the company’s strategic commitment to investing in immuno-oncology and building an innovative portfolio of cancer immunotherapies.
Precision BioSciences, Inc. Presents at 2015 SEBIO Investor & Partnering Forum, Nov-13-2015 09:45 AM
Nov 8 15
Precision BioSciences, Inc. Presents at 2015 SEBIO Investor & Partnering Forum, Nov-13-2015 09:45 AM. Venue: Belmond Charleston Place, 205 Meeting Street, Charleston, SC 29401, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|